This page is not for you if…
- You are having chest pain, trouble breathing, sudden weakness or numbness, trouble speaking, a sudden severe headache, or signs of a severe allergic reaction. Call 911 or go to an emergency room now. Unexplained vaginal bleeding needs prompt clinician evaluation, not a telehealth intake.
- You want a personal dose recommendation.We can't give you one, and no website can. We can tell you what the labels say and what to ask.
- You are already on HRT and think your dose is too low. Different problem. Signs your HRT dose may be too low
- You already know which product you want. Menostar patch online · Low-dose estradiol patch online · Where to buy vaginal estrogen online
This page is for you if:
- • You want to start cautiously and don't know which route fits your symptoms
- • You are staring at 4 mcg, 14 mcg, 0.025 mg, 0.0375 mg, or 0.5 mg and can't tell how they rank
- • You want online care but need to understand insurance, pharmacy, and medication differences first
- • You think you might be unusually sensitive to medication
- • You've been told “we'll start you on the lowest dose” and went home to look up what that means
Start here: which problem are you actually trying to solve?
Skip the dose numbers for a second. The route question comes first.
| What you want to fix | Route to ask about | Ultra-low or low-dose example | The thing that changes the answer |
|---|---|---|---|
| Hot flashes, night sweats | Systemic (whole-body) | Product-specific patch, or Bijuva 0.5 mg/100 mg oral | Once-weekly and twice-weekly patches do not use the same starting dose for hot flashes. |
| Painful sex, vaginal dryness | Local vaginal | Imvexxy 4 mcg insert | Approved for painful sex from vaginal atrophy — not for hot flashes. |
| Bone protection | Bone-focused systemic | Menostar 14 mcg/day patch | Not approved for hot flashes. Its label says to consider non-estrogen bone medicines first. |
| “I'm sensitive and don't know where to start” | Clinician picks the route with you | No universal product | Your symptom, uterus status, history, and state matter more than finding the smallest number. |
Symptom-to-route map. Sources cited in the product table below.
The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult. Where a fact isn't confirmed, we label it. We don't fill gaps with guesses.
Affiliate disclosure: We may earn a commission from some provider links on this page. Which providers we recommend follows The HRT Index Verification Standard — not payout.
Not sure which of the three routes fits you?
Most women can't answer the local / systemic / bone question cold, and there's no reason you should be able to. The right answer depends on symptoms, uterus status, history, and state — not the smallest number you can find.
Match my symptoms to the right HRT route →About 90 seconds. Personalized action plan — and a flag if your answers suggest online care isn't the right starting point. No email needed to see your result.
What counts as ultra low dose HRT?
Your brain does what every sensible brain does — it lines up 4 mcg, 14 mcg, 0.025 mg, and assumes gentler to stronger. They're not on the same line. They're not even in the same conversation. Micrograms (mcg) and milligrams (mg) are different units — 1,000 mcg equals 1 mg. The harder part is that a vaginal insert, a skin patch, and a swallowed capsule deliver estrogen to different places for different approved reasons. Ranking their numbers is like comparing the volume on your headphones to the volume on your car stereo. Same word. Different room.
So we did the tedious thing. We opened seven current FDA labels and put what they actually say in one place.
What each dose is FDA-approved to treat
| Product | Strength & schedule | Route | FDA-approved indication | Progestogen note if you have a uterus | Evidence status |
|---|---|---|---|---|---|
| Imvexxy 4 mcg | 4 mcg insert; daily for 2 weeks, then 2×/week | Vaginal (local) | Moderate-to-severe painful sex (dyspareunia) from vulvar and vaginal atrophy due to menopause | Local product — separate discussion from systemic estrogen | FDA-label verified |
| Imvexxy 10 mcg | 10 mcg insert; same schedule | Vaginal (local) | Same as 4 mcg | Same | FDA-label verified |
| Vagifem / Yuvafem 10 mcg | 10 mcg insert; daily 2 weeks, then 2×/week | Vaginal (local) | Atrophic vaginitis due to menopause | Local product — separate from systemic | FDA-label verified |
| Estring | 7.5 mcg/day; ring worn 90 days | Vaginal (local) | Urogenital symptoms of menopause | Local product — separate from systemic | FDA-label verified |
| Menostar | 0.014 mg/day (14 mcg); once weekly | Transdermal — systemic | Prevention of postmenopausal osteoporosis only. Hot flashes are not on its label. Label directs considering non-estrogen medicines first. | Label says clinicians should consider adding a progestogen | FDA-label verified |
| Climara 0.025 mg/day | 0.025 mg/day; once weekly | Transdermal — systemic | Moderate-to-severe hot flashes and osteoporosis prevention | Yes — clinician-determined | FDA-label verified |
| Twice-weekly patch 0.025 mg/day | 0.025 mg/day; changed 2×/week | Transdermal — systemic | On the current labels we checked: osteoporosis prevention. Hot-flash treatment commonly starts at 0.0375 mg/day. | Yes — clinician-determined | FDA-label verified |
| Bijuva 0.5 mg/100 mg | 0.5 mg estradiol + 100 mg progesterone; daily capsule | Oral — systemic, combined | Moderate-to-severe hot flashes in postmenopausal women with a uterus | Progesterone is in the capsule | FDA-label verified |
Sources: current FDA prescribing information via DailyMed and FDA accessdata.
The three meanings people mix together
Once you see it laid out, the confusion has a shape:
- Ultra-low local vaginal treatment — for vaginal and urinary symptoms
- Low-dose systemic symptom treatment — for hot flashes and night sweats
- Ultra-low bone-prevention treatment — for osteoporosis prevention
Three jobs. Three products. One phrase covering all of them. That's the whole mess in three lines.
What about blood levels? The honest version
Menostar's label states plainly (section 12.2) that a serum estrogen concentration generally does not predict an individual woman's response or her risk, and that comparing exposure across different estrogen products to infer effectiveness or safety for an individual woman may not be valid. (Menostar PI)
These studies used different products, different populations, different sample sizes, different measurement days, and different statistical measures. Here are the figures with the context they require, for readers who want them:
- Menostar 0.014 mg/day:geometric mean average serum estradiol (Cavg) of 13.7 pg/mL, in a pharmacokinetic study of 18 healthy postmenopausal women, mean age 66. (Menostar PI, section 12.3)
- Imvexxy 4 mcg:unadjusted day-14 mean Cavg of 3.6 pg/mL, versus 4.3 pg/mL in the placebo group, in a 54-woman pharmacokinetic subset. The label does not present that difference as evidence of lower risk. (Imvexxy PI)
- Vagifem 10 mcg:uncorrected mean Cavg of 5.5 pg/mL at day 83 in 29 women, with a coefficient of variation of 59.69% — meaning individual results varied widely. (Vagifem PI)
Which ultra-low-dose route matches your symptom?
Skip the milligrams for a second and answer one question: what do you want gone?
If it's hot flashes and night sweats → systemic
You need estrogen circulating through your body, because that's where the thermostat problem lives. That means a patch, gel, spray, or pill — not a vaginal insert. This is also where the ultra-low-dose instinct runs into trouble. We deal with that head-on in the next section.
→ Compare low-dose estradiol patches online
If it's painful sex, dryness, or vaginal discomfort → local vaginal
Ultra-low-dose vaginal estrogen is one of the most over-feared and under-used treatments in menopause care — both ACOG and The Menopause Society said so out loud in November 2025. Imvexxy 4 mcg is FDA-approved specifically for moderate-to-severe painful sex caused by menopausal vaginal changes. It is not a “weaker patch.” If this is your symptom, the smallest FDA-approved dose isn't a compromise — it's an option built precisely for you.
→ Where to buy vaginal estrogen online
If it's bone protection → a separate conversation entirely
Menostar is approved to prevent postmenopausal osteoporosis. Read its own Limitation of Use, because it's unusually direct: when prescribing solely to prevent osteoporosis, clinicians should first consider non-estrogen medicines, and consider estrogen only for women at significant risk. The label is telling your doctor to look at something else first. That's not a knock on the drug. That's the drug being honest about its lane.
If it's all of the above → prioritize, don't dose-shop
Mixed symptoms are normal. Local and systemic treatment may be used together under clinician guidance when they address different goals. But the sequence still matters:
- Name the symptom that's wrecking your life the most
- Figure out if it's systemic, local, bone-related, or unclear
- Flag anything in your history that changes the math
- Agree on the route
- Then talk about product and dose
Dose is step five. You're being asked to make it step one — that's why you're confused. It's not you.
That one question — local, systemic, or bone — decides everything else on this page. Most women can't answer it cold, and there's no reason you should be able to.
Match my symptoms to the right HRT route →About 90 seconds. You'll get a personalized action plan — and a flag if your answers suggest online care isn't the right starting point for you. No email needed.
Will ultra-low-dose HRT stop my hot flashes?
The 14 mcg patch isn't a gentle hot-flash treatment
Its FDA-approved indication is one line long: prevention of postmenopausal osteoporosis. Bayer ran a Phase 3 trial testing Menostar against hot flushes — 150 postmenopausal women, 12 weeks, placebo-controlled, with hot flush frequency as the primary outcome. It completed in November 2006. Twenty years later, the US label still doesn't carry a hot-flash indication. (NCT00185237)
What we can tell you is the fact that governs your prescription: the current approved label says osteoporosis prevention.That's the document your prescriber works from and your pharmacist fills against.
The 0.025 mg question has two different answers
A 0.025 mg/day patch is not one thing.
- Climara(once-weekly) lists 0.025 mg/day as a starting dose for moderate-to-severe hot flashes and for osteoporosis prevention.
- Twice-weekly patches — on the current labels we checked — commonly list 0.0375 mg/dayas the starting dose for hot flashes, with 0.025 mg/day appearing in the osteoporosis-prevention context.
Same number. Different wear schedule. Different labeled job. This is a real question to bring to your appointment:“Is my patch once-weekly or twice-weekly, and what is this strength approved to treat on that schedule?”
The low-dose option with a hot-flash approval built in
Bijuva 0.5 mg/100 mg— 0.5 mg estradiol with 100 mg progesterone in one capsule — is FDA-approved for moderate-to-severe hot flashes in postmenopausal women with a uterus. The progesterone is in the capsule, so when used as labeled, it doesn't require a separate progesterone prescription. The label reports one case of endometrial hyperplasia in the 0.5 mg/100 mg group — it isn't a guarantee; it's a design. It is also one of only six products whose label the FDA has actually updated — which matters more than it sounds, and is the next section.
What “lowest effective dose” honestly means
Not “the smallest number you can find.” It means: pick the right route for your symptom, start somewhere reasonable for that product, give it time, track what happens, adjust with your prescriber. The word effective was always doing the heavy lifting in that phrase, and everyone reads right past it.
Is ultra-low-dose HRT safer? What the FDA requested in 2025 — and which labels changed by 2026
The rule you're following is being retired
For more than twenty years, HRT labels carried an instruction: use the lowest effective dose for the shortest duration. That sentence built the mental model you walked in with. It's why “ultra-low-dose” felt responsible. It's why going smaller felt like being a good patient.
On , the FDA asked drug companies to take it out. (FDA Drug Safety Alert, 11/10/2025)
Not because low doses are bad. Because the blanket rule got stamped onto every dose, formulation, and route — including vaginal products — based on legacy warnings drawn heavily from two Women's Health Initiative trials of oral conjugated estrogens, with or without medroxyprogesterone acetate, in women aged 50 to 79 whose average age was 63.
The same FDA request also asked companies to add a line: consider starting hormone therapy for moderate-to-severe hot flashes in women under 60, or within 10 years of menopause. Dose is one lever. Route, timing, your uterus status, and your history are the others — and “ultra-low” only touches one of them.
What changed, and when
| Date | What happened |
|---|---|
| FDA convenes an expert panel on menopause and hormone therapy | |
| FDA requests class-wide label changes: remove cardiovascular, breast cancer, and probable dementia language from boxed warnings; remove endometrial cancer language exceptfor systemic estrogen-alone products; remove “lowest effective dose for the shortest amount of time”; add timing guidance for women under 60 or within 10 years of menopause | |
| FDA approves revised labeling for the first six products. FDA also reported that 29 companies had submitted proposed labeling changes. |
Sources: FDA Drug Safety Alert 11/10/2025; FDA press release 02/12/2026. Checked .
Which products have actually been updated — checked product by product
| Product | Route | On FDA's updated-label list? | Current label revision status | Checked |
|---|---|---|---|---|
| Prometrium | Oral progestogen | ✓ Yes | Revised labeling approved 02/12/2026 | |
| Divigel | Systemic estrogen alone | ✓ Yes | Revised labeling approved 02/12/2026 | |
| Cenestin | Systemic estrogen alone | ✓ Yes | Revised labeling approved 02/12/2026 | |
| Enjuvia | Systemic estrogen alone | ✓ Yes | Revised labeling approved 02/12/2026 | |
| Estring | Vaginal estrogen | ✓ Yes | Revised labeling approved 02/12/2026 | |
| Bijuva | Systemic estrogen + progestogen | ✓ Yes | Revised labeling approved 02/12/2026 | |
| Menostar | Transdermal systemic (14 mcg) | ✗ No | DailyMed page updated 03/12/2026; label revision date December 2023. Full original boxed warning present. "Lowest effective doses… shortest duration" language present. | |
| Imvexxy | Vaginal (4 / 10 mcg) | ✗ No | Not on FDA's updated list as of the date checked | |
| Vagifem | Vaginal (10 mcg) | ✗ No | Not on FDA's updated list as of the date checked |
Source: FDA, “Menopausal Hormone Therapies with Updated Prescribing Information” — FDA page content current as of ; product labels checked individually on DailyMed.
Where the experts agree — and where they don't
| Society | Ultra-low-dose vaginal | Systemic (including low-dose) |
|---|---|---|
| The Menopause Society (Nov 10, 2025) | Agrees with removing the boxed warning. Describes low-dose vaginal estrogen as a safe and effective therapy for a condition affecting most menopausal women, and says the warning may have deterred use. | More cautious. States systemic estrogen still carries potential risks in certain individuals that should be reviewed in detail before starting. |
| ACOG (Nov 2025) | Long advocated for removal. Says the warning made an effective treatment inaccessible and harmed patients. | Explicitly states systemic products have a different safety profile, are not without risk, and use should follow an individualized conversation. |
| SGO (Nov 20, 2025) | — | Notes FDA is not removing the endometrial cancer warning for systemic estrogen-alone products. |
Sources: The Menopause Society, ; ACOG, 11/2025; SGO, . Checked .
Do you need progesterone with ultra-low-dose estrogen?
A woman is misreading this label right now
On a Mayo Clinic Connect discussion thread dated , a woman using Menostar for osteoporosis wrote that the insert “seems to say that even with a uterus you can take it alone.”
Here is what the label actually says: when estrogen is prescribed for a postmenopausal woman with a uterus, clinicians should consider addition of a progestogen to reduce the risk of endometrial cancer. Section 5.7 explains why — adding a progestogen for 10 or more days of a cycle, or daily in a continuous regimen, has been reported to lower rates of endometrial hyperplasia, an overgrowth of the uterine lining that can precede endometrial cancer. (Menostar PI, sections 2 and 5.7)
“Ultra-low means I can skip the progesterone” is a genuinely dangerous idea. No systemic estrogen dose should be assumed to erase the endometrial-protection question for a woman with a uterus. The regimen stays product-specific and patient-specific.
Why this is the warning FDA kept
FDA asked for the endometrial cancer language to be removed except in systemic estrogen-alone drugs. They pulled cardiovascular. They pulled breast cancer. They pulled probable dementia. They kept this one.When an agency is actively removing warnings and leaves a specific one standing, that's worth reading closely.
If you've had a hysterectomy
The conversation changes — the Menostar label notes that generally, a woman without a uterus does not need a progestogen alongside estrogen. One exception worth knowing: women who've had a hysterectomy but have a history of endometriosis may still need one, because residual tissue can respond to estrogen. Ask about it if that's you. HRT after hysterectomy
Five questions for your appointment
- Is this local or systemic estrogen?
- Does my uterus status change this plan?
- Is progesterone part of this exact product, or a separate prescription?
- What is each part treating?
- What bleeding or side effects should make me call you?
Is compounded ultra-low-dose HRT FDA-approved?
Two different regulatory categories
| Question | FDA-approved finished drug | Compounded finished drug |
|---|---|---|
| FDA premarket review | Yes, for the approved product and its label | No |
| FDA-approved labeling | Yes | No approved finished-product label |
| FDA-reviewed product-specific pharmacokinetic data | Yes | No |
| Can meet a specific unmet clinical need | Sometimes | Yes — when a clinician determines an approved option doesn't fit |
| Can be called automatically safer or more natural | No | No |
Source: FDA, Compounding and the FDA: Questions and Answers. Checked .
503A and 503B — what those numbers mean
- 503A compounding pharmacies generally compound against patient-specific prescriptions. State boards of pharmacy provide primary day-to-day oversight. FDA retains inspection and enforcement authority— “state-regulated” does not mean FDA has no authority.
- 503B outsourcing facilities may compound certain drugs without patient-specific prescriptions and operate under additional federal requirements.
Neither category produces an FDA-approved finished drug. (FDA on compounding provisions)
When compounding has a real role
It solves genuine problems:
- The strength or dosage form you need isn't commercially available
- You're allergic to an ingredient in an approved product
- A specific clinician-determined need an approved product doesn't meet
The question to ask is whether compounding is solving a defined problem for you— or whether it's just how the product is marketed.
Can you get ultra low dose HRT online, and who actually prescribes it?
None of the public provider pages we checked list the 0.014 mg/day patch as a standard offering.The lowest systemic strengths we found published run to 0.025 mg/day. That doesn't prove no online clinician can prescribe it. It does mean you shouldn't expect to find it on a menu — and if you specifically need it, a prescription sent to your own pharmacy is likely the more reliable route.
What you can get online readily: ultra-low-dose vaginal estrogen. Low-dose systemic patches, gels, and pills. Combined products. Often FDA-approved, often through your pharmacy benefit.
The provider comparison
| Feature | Midi Health | Winona | Sesame | Hers |
|---|---|---|---|---|
| Model | Live video visit; prescription to your pharmacy | Async physician review; medication shipped | Marketplace — you pick a clinician; prescription to your pharmacy when appropriate | Digital subscription; medication shipped |
| Product type | States it prescribes FDA-approved bioidentical hormones (provider-published) | ⚠ ConflictingIts patch page and FAQ describe patches, tablets, and progesterone capsules as FDA-approved, while a Help Center page states Winona's treatments are not FDA approved. Creams are described as compounded. (conflicting — verify per product) | Depends on the clinician you choose and your pharmacy | Lists estradiol pills or patches, vaginal cream, and oral progesterone when appropriate (provider-published) |
| Lowest published systemic strength | Not confirmed in public materials | Patch page lists 0.025, 0.0375, 0.05, 0.075, 0.1 mg/day (provider-published; manufacturer and NDC unverified) | Clinician-dependent | Not confirmed |
| Carries 0.014 mg/day? | Not listed (not confirmed) | Not listed | Clinician-dependent | Not listed |
| Vaginal estrogen | Cream, tablet, ring (provider-published) | Limited | Clinician-dependent | Vaginal cream (provider-published) |
| Insurance | In-network with most PPO plans (provider-published) | Does not bill insurance; HSA/FSA may be reimbursable | Cash-pay marketplace | Cash-pay subscription |
| Medicaid / Medi-Cal | No — cannot treat Medicaid or Medi-Cal beneficiaries, including as self-pay (provider-published) | No | No | No |
| Medicare | Not covered. Self-pay possible; charges cannot be submitted to Medicare (provider-published) | No | No | No |
| States | All 50 states (provider-published; clinician availability varies) | 37 states + Puerto Rico; HRT program age range 35–59 (provider-published) | Varies by clinician | Not available in every state (provider-published) |
| Labs | Clinician-directed | Not required (provider-published) | Clinician-dependent | Clinician-dependent |
| Published price | $250 initial self-pay visit; $150 continued-care visit. Medication, labs, and pharmacy charges separate; insurance cost-sharing varies. (provider-published) | From $89/mo (estrogen + progesterone cream); $149/mo estradiol patch program (provider-published) | Menopause care displayed from $54/mo; medication not included (provider-published — capture a dated screenshot before publishing) | April 2026 announcement reported generic estradiol patch kits from $134/mo (provider-published; confirm at checkout) |
| Cancellation | Confirm at booking (not confirmed) | Full refund generally only within a stated 24-hour processing window; after that, orders generally cannot be canceled or refunded (provider-published) | Full refund generally requires cancellation at least 3 hours before the initial appointment; first month not refundable after the visit (provider-published) | Confirm at checkout (not confirmed) |
Sources: joinmidi.com/pricing-insurance; bywinona.com patch page and Winona FAQ; Sesame menopause care; Hers perimenopause. All provider-published and checked . Evidence status is marked per field — provider-published means the company says it, not that we independently confirmed it.
Why we resolve the Winona conflict by not resolving it
Winona's own current pages say two different things about FDA status. Its patch page and FAQ describe patches, tablets, and progesterone capsules as FDA-approved. A Help Center page states its treatments are not FDA approved. Before you classify any Winona product, confirm the exact product, manufacturer or NDC, dispensing pharmacy, and finished-product status.That's a real question to ask them, and it's a fair one.
→ Midi Health vs Winona: full comparison
The one honest problem with Midi
Midi Health does not bill Medicaid or Medi-Cal — and cannot treat Medicaid or Medi-Cal beneficiaries at this time, including as self-pay patients.Medicare is a partial no: you can be seen as self-pay, but you can't submit Midi charges to Medicare. That's from Midi's own site.
If that's your payment route, stop reading about Midi.That's a wall, not a hurdle, and we'd rather tell you now than after you've filled out an intake form.
Who should go somewhere else
- →You want a compounded cream specifically — Winona is purpose-built for that. Async, cash-pay, no bloodwork required. Confirm the product's regulatory status first.
- →You want a lower-cost single visit and your own pharmacy — Sesame lets you pick a clinician and price.
- →You want one digital subscription — Hers. Confirm state, strengths, and current price at checkout.
- →You need a specific named brand like Menostar or Imvexxy 4 mcg — no provider we reviewed publicly confirms carrying Menostar. A prescription to your own pharmacy is likely more reliable.
- →You have a clinician you like — use her. It costs you nothing extra and she knows your history.
In-network with most PPO plans · All 50 states · FDA-approved products
You know your route. You know what to ask for. You know what a good answer sounds like. The only thing left is finding out whether the coverage works — and that takes about a minute.
Check Midi coverage and current visit pricing →$250 initial self-pay visit, $150 continued care, or your plan's cost-sharing if in-network. Medication billed separately through your pharmacy. We may earn a commission.
How much does ultra low dose HRT online cost?
The advertised number is almost never the number.
Compare the model before the price
| Model | What you're buying | Where the surprise usually hides |
|---|---|---|
| Insurance-billed clinic (Midi) | Visits billed to your plan; prescription to your pharmacy | Medication is billed separately through your pharmacy benefit. The visit cost isn't the whole cost. |
| Cash subscription with medication (Winona, Hers) | Bundled review, medication, shipping | Intro rate vs. ongoing rate. When does the next charge hit, and when is the cancellation window? |
| Marketplace visit (Sesame) | One appointment; prescription to your pharmacy | Follow-up is a separate purchase. Continuity varies by clinician. |
| Your clinician + pharmacy | A visit and a prescription | Nothing bundled. Often cheapest if you have coverage. |
Do this math: your real first 90 days
Write down every line. Then total it.
- Initial visit
- Membership or subscription fee
- Medication
- Labs, if required
- Shipping
- First follow-up
- Any required refill visit
- Intro discount — and the standard rate after it ends
- Cancellation cutoff date
Then compute first 30 days, first 90 days, and ongoing monthly. That's the number. Almost nobody calculates it, which is precisely why programs advertise the other one. If a line is unknown, don't estimate it — go get it.
Insurance vs. cash — the honest version
An insurance-accepting clinic doesn't guarantee your visit or your medication is covered. A cash-pay provider is simpler but not automatically cheaper. Coverage varies by plan, product, diagnosis, and pharmacy benefit — including for vaginal estrogen, which some plans handle differently from systemic HRT. Check yours; don't assume either way.
12 questions. Get all 12 answered before you pay anyone.
Any provider worth your money can answer every one of these.
- What exact medication might be prescribed?
- What strength and route?
- Is the finished product FDA-approved or compounded?
- What symptom is it treating?
- Does my uterus status change the plan?
- Who reviews my case, and what are their credentials?
- Is a live visit required?
- Which pharmacy dispenses it?
- What is my total cost for the first 90 days?
- What follow-up is included?
- How do I reach someone about side effects?
- When must I cancel to avoid the next charge?
Free — no email needed to see your result.
What if you can't actually fill it?
Two authorities, two answers
| Source | Position | Dated |
|---|---|---|
| FDA | Had not formally designated a national estradiol patch shortage. Manufacturers described as operating at capacity while working to meet increased demand. | Mid-2026 |
| ASHP | Listed specific estradiol transdermal presentations as a current shortage, including named manufacturer back orders and allocation status. |
Sources: ASHP Drug Shortage Database — Estradiol Transdermal System; FDA position as reported in national coverage. Checked .
Women are reporting real trouble filling patch prescriptions right now, and this is not evenly distributed.It is manufacturer-, strength-, package-, and pharmacy-specific. And it isn't only patches — ASHP separately listed estradiol vaginal cream as a current shortage in . A patch shortage doesn't mean every vaginal product is fine.
Why this is happening
Demand rose sharply. Prescriptions for estrogen-based therapy among women aged 45–54 rose approximately 25.7% between July 2025 and February 2026 alone, per Truveta data. What happened in November 2025? The FDA requested the boxed-warning changes. You are not unlucky. You are part of a crowd that all made the same reasonable decision at the same time.
What to do about it
If your pharmacy says backordered, don't go without and don't improvise. A prescriber or pharmacist may consider:
- A different manufacturer or package size
- A different pharmacy
- A once-weekly system instead of twice-weekly, or the reverse
- A non-patch route — gel, spray, or oral — when clinically appropriate
These are not interchangeable by arithmetic. Routes differ, and switching from a patch to a pill isn't a clean swap for everyone — oral estrogen passes through the liver first, which matters if you were put on a patch for that reason specifically. That is a clinical conversation. Do not cut patches, change your wear schedule, or stretch a supply. Call your prescriber or pharmacist, not a forum.
→ What to do if you miss an estradiol patch dose
A provider who can prescribe across forms is worth more right now
This is the kind of thing that doesn't matter until it matters — which is at 5pm on a Friday when the pharmacy says no. Midi's clinicians prescribe across patches, pills, gels, and vaginal forms, in all 50 states. Nobody can guarantee stock. But having a prescriber who can pivot the form is the difference between a phone call and a month without.
See what Midi's clinicians prescribe in your state →We may earn a commission. Medicaid / Medi-Cal beneficiaries cannot use Midi — see note above.
How long before you know if it's working?
| Product | What the label's trial measured | When |
|---|---|---|
| Imvexxy | Primary painful-sex endpoint | Week 12 |
| Bijuva | Hot-flash outcomes | Weeks 4 and 12 |
| Menostar | Bone mineral density | 12 and 24 months |
These are label assessment schedules, not a speed ranking. Sources: current prescribing information for each product. Checked .
If you are on a bone medication expecting your hot flashes to stop next Tuesday, nothing has gone wrong. It is doing what it does.
Track these
Symptom type. How often. How bad. Sleep interruptions. Vaginal discomfort. Any bleeding. New side effects. Whether the patch stayed on. The date you started. Questions as they come up. A concise symptom record makes a short follow-up considerably more useful.
Why “nothing's happening yet” isn't a reason to self-adjust
A clinician-guided dose increase is part of titration. It isn't evidence that treatment failed, and it isn't a mark against you. The starting dose was a starting point. That is what the word means. It does still change your exposure, and it may change benefits, side effects, bleeding, and the rest of your regimen — which is exactly why it is a conversation with your prescriber and not a decision you make alone at 11pm.
Call sooner if:
- New or significant bleeding
- A severe or worrying side effect
- The patch won't stick
- The medication you received doesn't match what was prescribed
- You are not sure how to use it
- Your mood changes in a way that concerns you
What side effects and warning signs matter even at a low dose?
Call 911 or go to an emergency room now
Do not wait for a telehealth appointment. Do not message a portal.
- Chest pain or pressure
- Trouble breathing
- Sudden weakness or numbness, especially on one side
- Trouble speaking or understanding speech
- Sudden severe headache
- Sudden vision loss or major vision change
- Signs of a severe allergic reaction — swelling of the face, lips, or throat, or trouble breathing
These can be signs of a blood clot, stroke, heart attack, or severe allergic reaction. Estrogen labels carry warnings about clot, stroke, and cardiovascular events. (Menostar PI, section 5.1)
Contact your prescriber promptly
- Unexplained vaginal bleeding — this needs evaluation, not a wait-and-see. It is also a listed contraindication to starting estrogen therapy.
- New breast lump, pain, or change
- A side effect that is persistent or getting worse
- A significant mood change
- Patch reaction or a patch that won't stay on
- You are not sure how to use the product
Common effects are product-specific. Estrogen labels list effects including headache, breast pain and tenderness, nausea, and vomiting. Read the medication guide for the exact product you are given, and ask your pharmacist what is expected versus what is a reason to call. “Ultra-low” is not a synonym for “risk-free.” The right dose is a benefit-risk decision made with a clinician who knows your history.
Who should start in person instead of online?
These require clinician evaluation before any estrogen therapy — straight from the Menostar label's contraindications:
- Undiagnosed abnormal genital bleeding
- Breast cancer, or a history of it
- Estrogen-dependent tumors
- Active blood clots (DVT or PE), or a history of them
- Active arterial disease — stroke or heart attack — or a history of it
- Liver impairment or disease
- Protein C, protein S, or antithrombin deficiency, or other known clotting disorders
- A known allergic reaction to the product
- Possible pregnancy, or any symptom that needs someone to physically examine you
If you are over 60 or more than 10 years past menopause
The FDA's requested labeling guidance points toward starting systemic hormone therapy under 60, or within 10 years of menopause. That is about starting, and it reflects where the benefit-risk balance appears most favorable. It doesn't mean you are out of options. A 76-year-old woman on a Mayo Clinic Connect thread described being told she couldn't take estrogen because of her age — while being prescribed Menostar for her bones. That is not a contradiction. It is a nuanced decision that belongs with a clinician who knows her whole history. Don't let a website — including this one — write you off.
If your answers suggest you should see someone in person first, the tool tells you that. It won't route you to a provider.
Check whether online care fits your situation →What we actually verified
What we did, on :
- Read the current FDA prescribing information for Menostar, Imvexxy, Vagifem, Estring, Climara, twice-weekly estradiol patch labeling, and Bijuva on DailyMed and FDA accessdata. Every indication, schedule, and figure in our tables came from those labels.
- Checked each product against the FDA's published list of menopausal hormone therapies with updated prescribing information (FDA page content current as of )
- Read the FDA's November 10, 2025 labeling-change request and the February 12, 2026 approval announcement in full
- Read the public statements from The Menopause Society, ACOG, and SGO
- Read provider-published pricing, formulary, insurance, state, and cancellation terms directly from Midi Health's, Winona's, Sesame's, and Hers' own sites
- Compared the FDA's shortage position against the ASHP drug shortage database
What we did not do:
- We did not test these products
- We did not complete a paid intake, receive a prescription, or test a cancellation flow
- We did not verify pharmacy stock in your area
- This page is independent editorial research. It is not medical advice and has not been reviewed by a clinician.
What we could not confirm:
- Midi's exact lowest patch and oral strengths, and whether Menostar, Imvexxy 4 mcg, or Bijuva 0.5/100 can be prescribed on request — not confirmed in public materials
- Winona's exact patch manufacturer, NDC, and dispensing source — provider-published strengths only
- Winona's own pages conflict on FDA status — unresolved; confirm per product
- Sesame's exact local clinician pricing — varies
- Hers' current checkout price, exact strengths, and state list — not confirmed
The HRT Index Verification Standard
Our documented process: we read every published price, separate FDA-approved from compounded, verify state availability and insurance, and re-check on a fixed schedule — top providers monthly, full roster quarterly. We evaluate providers on exactly five pillars, always in this order: clinical legitimacy, care quality, medication fit, price transparency, access. Every field in our provider table carries an evidence status. Provider-published means the company says it. FDA-label verified means we read it in the label. Conflicting means two current sources disagree and we are not choosing for you. Not confirmed means exactly that.
What would change our answer
- If more ultra-low-dose products get updated labels, the label-status table changes. We check the FDA tracker monthly.
- If the patch shortage resolves or FDA and ASHP converge, we will say so.
- If Winona clarifies its FDA-status contradiction, we will update the classification.
- If Midi's formulary or Medicaid position changes, our recommendation changes with it.
Frequently asked questions
- What is the smallest HRT dose you can take?
- There is no single answer because it depends on the route. The smallest FDA-approved vaginal estradiol dose is Imvexxy 4 mcg. The smallest FDA-approved systemic transdermal dose is 0.014 mg/day, sold as Menostar. They are approved to treat different conditions.
- Is a 0.025 mg estradiol patch ultra-low dose?
- It is a low systemic strength, but its labeled job depends on the product. Climara's once-weekly label lists 0.025 mg/day as a starting dose for hot flashes and osteoporosis prevention. The current twice-weekly labels we checked start hot-flash treatment at 0.0375 mg/day. Ask which patch you were prescribed and what that specific schedule is approved to treat.
- Does Menostar 14 mcg treat hot flashes?
- No. Its FDA-approved indication is prevention of postmenopausal osteoporosis. Hot flashes are not on its label.
- Is there a generic for Menostar?
- Yes. The FDA approved a generic estradiol transdermal system, 0.014 mg/day, referencing Menostar in April 2023. FDA approval does not guarantee your pharmacy stocks it — confirm availability.
- Is Menostar available online?
- Possibly through any appropriately licensed prescriber, but no online provider we reviewed publicly lists it. If you need it specifically, a prescription to your own pharmacy is likely more reliable.
- Is 4 mcg vaginal estrogen enough?
- For its labeled use — moderate-to-severe painful sex from menopausal vaginal changes — 4 mcg is an FDA-approved strength that was superior to placebo at week 12 in the label's trial. Whether it is right for you is an individual clinical decision.
- Can you use vaginal and systemic estrogen together?
- They may be used together under clinician guidance when they address different treatment goals. That is a conversation to have with your prescriber, not something to arrange on your own.
- Do I need progesterone with a 0.025 mg patch?
- If you have a uterus and you are using systemic estrogen, the endometrial question applies regardless of how low the dose is. The regimen is product- and patient-specific, and your clinician determines it.
- Is a lower dose always safer?
- No dose is risk-free, and the smallest number may simply fail to treat your symptom. In November 2025 the FDA asked manufacturers to remove the blanket 'lowest effective dose for the shortest duration' instruction — partly because it was applied to products and routes it never fit.
- Can I cut an estradiol patch in half?
- Not on your own. Patch construction varies, and some products cannot be cut without changing how the medication is delivered. Ask your pharmacist or prescriber.
- Are labs required before starting HRT online?
- It depends on the provider and your history. Winona states it does not require bloodwork. Midi's clinicians decide case by case. Neither approach is automatically right — the provider should explain what is required and why before you pay.
- Can I get low-dose HRT online without insurance?
- Yes. Cash-pay and marketplace models exist. Compare the full 90-day cost, not the advertised monthly rate, and find the cancellation window before you enroll.
- Is compounded microdose HRT FDA-approved?
- No. Compounded finished drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing the way approved drugs are. Compounding is legal and can meet a specific clinical need. 'Microdose' is not an FDA category.
- What if the lowest dose doesn't help?
- Track your symptoms and talk to your prescriber about adjusting. A clinician-guided increase is part of titration, not a failure. Do not change the dose, schedule, or your progestogen plan on your own.
- When is online care not the right first step?
- Unexplained bleeding, a history of breast cancer or blood clots, active liver disease, possible pregnancy, or any symptom needing a physical exam. Acute symptoms like chest pain or sudden weakness mean emergency care — call 911 — not an appointment.
If you take one thing from this page
Your instinct to start small was right. It was just pointed at one dial out of several.
The question was never how many milligrams. It is which of these three medicines your symptom actually calls for — and whether route, timing, and your history are on your side. That is answerable. Often in one appointment.
And here is the part we would want someone to tell us: the sentence that sent you looking for the smallest possible dose — lowest effective dose, shortest duration— is the sentence the FDA asked to have removed in November 2025. You were following a rule that is being retired. You just hadn't been told. Now you have. Go have the conversation.
Still not sure which HRT program is right for you?
Take our free 90-second matching quiz. No email needed to see your result.
Get my personalized HRT action plan →The HRT Index is the independent menopause HRT decision layer for women. Educational only — not medical advice. Not reviewed by a clinician.
Primary sources are linked inline throughout this page. Medication facts come from current FDA prescribing information via DailyMed and accessdata.fda.gov. Regulatory facts come from FDA announcements. Provider facts are provider-published and dated. Where sources conflict, we show both.